Overview

Trial of Andexanet Alfa in ICH Patients Receiving an Oral FXa Inhibitor

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant
Phase:
Phase 4
Details
Lead Sponsor:
Alexion Pharmaceuticals
Portola Pharmaceuticals
Collaborator:
Population Health Research Institute